Menu Close

Biologics have been a treatment option for patients living with disabling and life-threatening chronic diseases for more than 20 years. Today, there are biosimilar versions of originator biologics available to people living with these health challenges. Thirty-six biosimilar biologics are currently approved by Health Canada for chronic diseases, including inflammatory arthritis, cancer, inflammatory bowel disease, diabetes and psoriasis.

Arthritis Consumer Experts (ACE) has been a leader in biosimilars policy development discussions since 2009, sharing information with stakeholders across Canada through free research-based workshops, webinars and education programs. Drawing from this experience, ACE has created the Biosimilars•Exchange, an information hub for consumers to get the latest biosimilar biologics news and background analysis.

With research-based information and education, patients can have a full therapy conversation with their rheumatologist (or other specialist) in order to best decide on their choice of medication, including originator biologic or biosimilar biologic.

Biosimilars should have a positive effect for both the healthcare system and patients; they can broaden access for patients who need advanced therapy and address the significant and growing cost of biologics.  

As biosimilars research data continues to be published and policies regulating them evolve, ACE is meeting with public and private drug plan decision makers to advocate for biosimilar cost savings to be reinvested to improve models of care for patients living with complex chronic diseases.

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.

This site complies with the HONcode standard for trustworthy health information: verify here.

Arthritis Consumer Experts
© 2000-2021

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.

This site complies with the HONcode standard for trustworthy health information: verify here.

Arthritis Consumer Experts
© 2000-2021

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.

This site complies with the HONcode standard for trustworthy health information: verify here.